Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVID200 in Diffuse Cutaneous Systemic Sclerosis
NCT03831438Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2019
- Primary completion
- Jun 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AVID200 in diffuse cutaneous systemic sclerosis (dcSSc), sponsored by Bristol Myers Squibb. Primary endpoint: Incidence of treatment related adverse events at 10 Months. Started Jan 2019; status: completed.
02
Drugs
AVID200
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT03831438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03831438.